Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

• Hauptverfasser: Alistair Ring (Verfasst von), Meghan Karuturi (Verfasst von), Emily Nash Smyth (Verfasst von), Tasneem Lokhandwala (Verfasst von), Kristin M. Sheffield (Verfasst von), Joanne Willey (Verfasst von), Orsolya Lunacsek (Verfasst von), Francisco Sapunar (Verfasst von), Zhanglin Lin Cui (Verfasst von), Anna D. Coutinho (Verfasst von), Sarah Rybowski (Verfasst von)
• Format: Buch
• Veröffentlicht: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Introduction Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) is the most frequently diagnosed metastatic breast cancer (mBC) subtype. Combinations of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4 & 6is) improve outcome...